Twelve patients suffering from Ta-T1, N0 M0, G1-2, transitional cell carcinoma of the bladder received intravesical instillations of polyethylene-glycol-modified interleukin-2 (PEG-IL2) with tumor in situ (1/week x 6). An interpatient dose escalation scheme from 6 to 24 x 106 IU was used in four groups of three patients each. Transurethral resection of the bladder tumor was carried out 7-15 days after the last PEG-IL2 dose. Five out of twelve patients showed partial regression of the bladder neoplasm; stable disease was observed in the remaining 7; no tumor progression occurred. Two patients showed local tumor relapse 3 months after transurethral resection; no evidence of disease was found in the remaining 10 patients after 3-12 months follow-up (median 6, mean 7.5).
|Translated title of the contribution||Polyethyleneglycol-modified interleukin-2 in the treatment of superficial neoplasia of the bladder: Study in phase IB|
|Number of pages||2|
|Journal||Acta Urologica Italica|
|Issue number||SUPPL. 2|
|Publication status||Published - 1993|
ASJC Scopus subject areas